Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2025. "We're reporting another ...

Patients with chronic kidney disease and those on dialysis have chronic pain and want to talk about it with their nephrologist, according to Hesham Y. Shaban, MD, a palliative care and nephrology ...

Suboptimal dialysis initiation, typically defined as dialysis initiation during a hospitalization and/or with a central venous catheter, is common among patients with advanced chronic kidney ...

For people with kidney failure, home dialysis can offer more freedom and better quality of life. So what’s stopping the NHS from supporting more people to choose it?

ProKidney’s cell therapy for kidney disease failed to demonstrate a clinically significant preservation of kidney function in one part of the study.

He further said that the non-dialysis CKD market shows another notable opportunity for the company, dependent on the success of the Phase 3 VALOR trial, anticipated to start in H2 2025.

He further said that the non-dialysis CKD market shows another notable opportunity for the company, dependent on the success of the Phase 3 VALOR trial, anticipated to start in H2 2025.

Foreign service officers face new hiring criteria as State Department removes DEI requirements and adds "fidelity" as a core precept, part of efforts to restructure the department.

The FDA has rejected Unicycive's kidney disease drug due to manufacturing issues. The company is seeking a new manufacturer and plans a meeting with the FDA to resolve the agency’s concerns.

For CKD patients undergoing dialysis treatment, the regular dialysis is not sufficient to remove the overload of serum phosphate in the body.